G. Cairncross

Phase II study of topotecan in patients with recurrent malignant glioma

David Macdonald, G. Cairncross, David J. Stewart et al. · Annals of Oncology · 1996 · 74 citations · Full text

Neuro-oncology, Malignant Disease, Recurrent Malignant Glioma +12

Small molecule epigenetic screen identifies novel EZH2 and HDAC inhibitors that target glioblastoma brain tumor-initiating cells

Natalie Grinshtein, Constanza Rioseco, Richard Marcellus et al. · Oncotarget · 2016 · 47 citations · Full text

Phase II trial of docetaxel in patients with recurrent malignant glioma: a study of the National Cancer Institute of Canada Clinical Trials Group

Peter Forsyth, G. Cairncross, David J. Stewart et al. · Investigational New Drugs · 1996 · 45 citations

Neuro-oncology, National Cancer Institute, Phase Ii Trial +11

An intergroup randomized controlled clinical trial (RCT) of chemotherapy plus radiation (RT) versus RT alone for pure and mixed anaplastic oligodendrogliomas: Initial report of RTOG 94–02

G. Cairncross, Wendy Seiferheld, Emily Shaw et al. · Journal of Clinical Oncology · 2004 · 44 citations

Progression-free Survival, Surgical Oncology, Anaplastic Oligodendrogliomas +24

A feasibility study to assess the integration of a pharmacist into neurooncology clinic

Louise Delaney, Carole Chambers, Glòria Roldán et al. · Journal of Oncology Pharmacy Practice · 2008 · 23 citations